Onward Medical N.V. (ONWD.BR)
EUR 4.74
(-0.21%)
EUR 4.74
(-0.21%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -12.89 Million EUR | 52.91% |
| 2022 | -27.38 Million EUR | 63.86% |
| 2021 | -75.77 Million EUR | -312.66% |
| 2020 | 35.63 Million EUR | 90.82% |
| 2019 | 18.67 Million EUR | 109.87% |
| 2018 | 8.89 Million EUR | 162.56% |
| 2017 | 3.38 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -7.23 Million EUR | 15.14% |
| 2024 Q1 | -8.53 Million EUR | 33.84% |
| 2023 Q4 | -12.89 Million EUR | 4.22% |
| 2023 Q1 | -3.42 Million EUR | 87.51% |
| 2023 FY | -12.89 Million EUR | 52.91% |
| 2023 Q3 | -13.46 Million EUR | -358.51% |
| 2023 Q2 | -2.93 Million EUR | 14.18% |
| 2022 Q3 | -27.81 Million EUR | 55.76% |
| 2022 Q2 | -62.86 Million EUR | 0.67% |
| 2022 Q4 | -27.38 Million EUR | 1.54% |
| 2022 Q1 | -63.28 Million EUR | 16.49% |
| 2022 FY | -27.38 Million EUR | 63.86% |
| 2021 Q4 | -75.77 Million EUR | 0.62% |
| 2021 FY | -75.77 Million EUR | -312.66% |
| 2021 Q3 | -76.25 Million EUR | -275.1% |
| 2021 Q2 | 43.54 Million EUR | 0.3% |
| 2021 Q1 | 43.41 Million EUR | 21.84% |
| 2020 Q4 | 35.63 Million EUR | 0.39% |
| 2020 Q3 | 35.49 Million EUR | 0.0% |
| 2020 Q1 | 15.12 Million EUR | 0.0% |
| 2020 FY | 35.63 Million EUR | 90.82% |
| 2019 FY | 18.67 Million EUR | 109.87% |
| 2018 FY | 8.89 Million EUR | 162.56% |
| 2017 FY | 3.38 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | -1705.882% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 93.437% |
| Adocia SA | 127 Thousand EUR | 10252.756% |
| Aelis Farma SA | -16.19 Million EUR | 20.368% |
| Biophytis S.A. | 2.7 Million EUR | 577.026% |
| Advicenne S.A. | 12.17 Million EUR | 205.906% |
| genOway Société anonyme | 2.97 Million EUR | 533.708% |
| IntegraGen SA | -709.74 Thousand EUR | -1716.699% |
| Medesis Pharma S.A. | 1.15 Million EUR | 1213.27% |
| Neovacs S.A. | -237.08 Thousand EUR | -5338.51% |
| NFL Biosciences SA | -2.27 Million EUR | -466.553% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 395.971% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | -1452.469% |
| Sensorion SA | 1.37 Million EUR | 1035.553% |
| Theranexus Société Anonyme | 2.44 Million EUR | 627.544% |
| TME Pharma N.V. | -1.07 Million EUR | -1094.995% |
| Valbiotis SA | -18.13 Million EUR | 28.916% |
| TheraVet SA | 12.78 Thousand EUR | 100952.562% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 691.468% |
| argenx SE | -1.83 Billion EUR | 99.298% |
| BioSenic S.A. | 28.04 Million EUR | 145.978% |
| Celyad Oncology SA | -6.1 Million EUR | -111.308% |
| DBV Technologies S.A. | -114.95 Million USD | 88.784% |
| Galapagos NV | -157.2 Million EUR | 91.798% |
| Genfit S.A. | -7.61 Million EUR | -69.413% |
| GeNeuro SA | 5.91 Million EUR | 318.158% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 48.654% |
| Innate Pharma S.A. | -30.71 Million EUR | 58.016% |
| Inventiva S.A. | 10.48 Million EUR | 222.929% |
| MaaT Pharma SA | -10.2 Million EUR | -26.35% |
| MedinCell S.A. | 39.5 Million EUR | 132.642% |
| Nanobiotix S.A. | -24.71 Million EUR | 47.836% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 1001.468% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 147.528% |
| Oxurion NV | 10.71 Million EUR | 220.392% |
| Pharming Group N.V. | 99.4 Million EUR | 112.972% |
| Poxel S.A. | 44.55 Million EUR | 128.937% |
| GenSight Biologics S.A. | 16.29 Million EUR | 179.133% |
| Transgene SA | -14.4 Million EUR | 10.514% |
| Financière de Tubize SA | 78.62 Million EUR | 116.399% |
| UCB SA | 2.17 Billion EUR | 100.592% |
| Valneva SE | 82.73 Million EUR | 115.585% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 30.393% |